N-<3-(Methoxycarbonyl)-propyl>-succinimid | 71835-02-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-<3-(Methoxycarbonyl)-propyl>-succinimid
• 英文别名: Methyl 4-(2,5-dioxopyrrolidin-1-yl)butanoate
• CAS: 71835-02-4
• 化学式: C₉H₁₃NO₄
• 分子量: 199.207
• InChiKey: SFIQQXSUVXRYTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-<3-(Methoxycarbonyl)-propyl>-succinimid 、 三氟甲磺酸三甲基硅酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以30%的产率得到methyl (+/-)-(3R,αR)-4-(2,5-dioxo-3-trimethylsilyl-1-pyrrolidinyl)-(α-trimethylsilyl)butanoate
  参考文献：
  名称：

  Silylative Dieckmann-Like Cyclizations of Ester-Imides (and Diesters)

  摘要：

  Trialkylsilyl triflates effect cyclization of ester-imides such as 2 to produce adducts such as 4a. Trapping of the in situ generated, nucleophilic ketene acetal (cf. 5a) is a key aspect of the transformation. A range of substrates amenable to this operationally simple reaction is reported. In many instances the levels of diastereoselectivity are very high. Mechanistic points are inferred from spectroscopic observations.

  DOI：

  10.1021/ol061988q

文献信息

• SITE-SPECIFIC INSULIN CONJUGATE
  申请人：Hanmi Pharm. Co., Ltd.

  公开号：EP2963055A1

  公开（公告）日：2016-01-06

  Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.

  本发明提供了一种具有改进的胰岛素受体结合亲和力和更高活性的胰岛素共轭物，其中非肽聚合物和免疫球蛋白Fc区通过共价键与胰岛素β链的氨基酸残基（不包括其N-末端）定点特异性连接，还提供了包括本发明在内的长效制剂及其制备方法。本发明的胰岛素共轭物可用于提供一种胰岛素制剂，该制剂可显著提高肽的体内活性。
• THERAPEUTIC USES OF GLUCAGON AND COMBINED PRODUCT COMPRISING SAME
  申请人：Hanmi Pharm. Co., Ltd.

  公开号：EP3862019A1

  公开（公告）日：2021-08-11

  Provided are a combination including glucagon and a compound or substance with therapeutic activity against a metabolic syndrome and a use thereof.

  本文提供了一种包括胰高血糖素和对代谢综合征具有治疗活性的化合物或物质的组合物及其用途。
• COMPOSITION AND KITS FOR PSEUDOPLASTIC MICROGEL MATRICES
  申请人：Rochal Industries, LLC

  公开号：EP3283057B1

  公开（公告）日：2021-07-28
• OXYNTOMODULIN PEPTIDE ANALOG FORMULATIONS
  申请人：EirGen Pharma Ltd.

  公开号：EP3886807A2

  公开（公告）日：2021-10-06
• BLOOD PLASMA BASED HYDROGELS FOR TISSUE REGENERATION AND WOUND HEALING APPLICATIONS
  申请人：Board of Regents, The University of Texas System

  公开号：US20140065121A1

  公开（公告）日：2014-03-06

  The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications.